-
Review of Ceftriaxone Sodium for Injection and Lansoprazole for Injection in Shanghai Pharmaceuticals
Time of Update: 2021-08-16
In May 2018, Shanghai Pharmaceutical Xinya submitted an application to the State Food and Drug Administration for the consistency evaluation of generic ceftriaxone sodium for injection and was accepted .
-
Amgen Carfilzomi is about to be approved in China
Time of Update: 2021-08-16
Carfilzomib (Kyprolis) is a proteasome inhibitor .
The proteasome can break down damaged or no longer needed proteins, and it plays an important role in the normal function and growth of cells .
-
BeiGene tislelizumab's new indications will be included in the priority review
Time of Update: 2021-08-15
The trial aims to evaluate the efficacy and safety of tislelizumab in the treatment of previously treated, locally advanced unresectable or metastatic MSI-H or dMMR solid tumor patients.
-
Opportunities for pharmaceutical companies to introduce heavy policies
Time of Update: 2021-08-15
After the Drug Approval Center releases technical documents supporting the development of children's drugs with real-world evidence, hospitals can collect past clinical application data and use real-world data research results to bring medical institution preparations to the market .
-
GSK announces results of Phase 3 clinical study of two-in-one drug Dovato in the treatment of HIV-1 adult patients
Time of Update: 2021-08-15
The results showed that in a diverse group of adult HIV-1 patients who have achieved virological suppression and have not previously experienced virological failure, switch to a single-tablet two-drug regimen (2DR) Dovato (Chinese trade name: Dovito®, Generic name: dolutegravir/lamivudine tablets, dolutegravir/lamivudine, DTG/3TC, 50mg/300mg), compared with continuing to receive the current broad antiretroviral regimen (CAR) consisting of at least 3 drugs, The efficacy showed non-inferiority, no patients had virological failure, and no patients developed drug resistance .
-
Several licensed pharmacists were cancelled
Time of Update: 2021-08-15
On November 30 last year, the Gansu Provincial Food and Drug Administration issued an announcement stating that in accordance with relevant laws and regulations, it has decided to compulsorily cancel the licensed pharmacist registration certificate of Zhang’s licensed pharmacist (Zhang, female, licensed pharmacist).
-
PD-1/TIGIT bispecific antibody enters clinical joint development by Cinda and Eli Lilly
Time of Update: 2021-08-15
On July 25, 2021, Innovent Biologics announced that in patients with advanced malignant tumors, its phase 1a clinical trial of the anti-PD-1/TIGIT bispecific antibody IBI321 has completed the first patient administration .
Retrieved July 25, 2021, from https:// /news-releases/innovent-announces-the-first-patient-dosed-in-the-phase-1-study-of-ibi321-anti-pd-1tigit-bispecific-antibody-in-patients-with-advanced-malignant -tumors-301340637.
-
Sanofi's new indication for Duplizumab is about to be approved
Time of Update: 2021-08-15
In March 2017, Duplizumab was approved by the FDA to become the first targeted biologic drug for the treatment of moderate to severe atopic dermatitis in adults.
On June 17, 2020, Duplizumab was approved in China for the treatment of moderate to severe atopic dermatitis in adults .
-
The State Food and Drug Administration has conditionally approved the listing of Azivudine Tablets, a new AIDS class 1 drug
Time of Update: 2021-08-15
The drug is used in combination with nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors to treat adult HIV-1 infected patients with high viral loads .
Azvudine is a novel nucleoside reverse transcriptase and accessory protein Vif inhibitor, and it is also the first dual-target anti-HIV-1 drug mentioned above .
-
Luye Pharma and Yuli Pharmaceutical reached a cooperation agreement
Time of Update: 2021-08-15
In addition, Seroquel sustained-release tablets have also been approved in some areas for the treatment of depression and generalized anxiety disorder .
-
1 billion dollars!
Time of Update: 2021-08-15
The two companies' non-insulin glucose control injections Trulicity and Victoza have been competing fiercely for market share for many years, as well as other similar long-acting insulin products Basaglar and Tresiba launched by Eli Lilly and Novo Nordisk .
The glucose-responsive insulin developed by Eli Lilly and Novo Nordisk can solve the clinical needs of the diabetes market .
-
The important basis for the hospital to take medicine is here!
Time of Update: 2021-08-15
Medical Network News on August 4th. The relevant evidence of clinical comprehensive evaluation will become evidence that medical institutions refuse to enter certain drugs into this institution. Ho
-
Eli Lilly Olumiant's application for new indications is delayed in the U.S. review
Time of Update: 2021-08-15
As of now, Olumiant has been used in more than 75 countries (including The United States, China, the European Union, and Japan have been approved and marketed for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) .
-
The salary of pharmacy executives announced the highest over 2.49 million
Time of Update: 2021-08-15
49 million yuan, ranked firstThe chairman and deputy general manager of Dashenlin, with an annual salary of over 2.
Among them, Chairman Ke Yunfeng (54 years old) and Dashenlin Deputy General Manager Ke Jinlong (51 years old) rank 89th on the list with an annual salary of 2.
-
Takeda's new oral small molecule drug mobocertinib capsule is included in priority review in China
Time of Update: 2021-08-15
It was awarded a breakthrough therapy designation by the FDA in April 2020 for the treatment of patients with EGFR Exon20 insertion mutation NSCLC who had disease progression during or after platinum-containing chemotherapy .
-
Drugstore owner sentenced to 4 years imprisonment for misdispensing medicines, compensation 1.1 million
Time of Update: 2021-08-15
According to relevant information, the defendant in this case was the owner of a local pharmacy, Qin Moumou, who taught himself to become a doctor since he was a child, and started a Chinese herbal medicine business without formal medical training and without a business license .
-
Domestic Infliximab is on the market, the autoimmune field is intensified
Time of Update: 2021-08-15
Leike domestic sample hospital sales (ten thousand yuan)Data source: Wind Medical LibraryWith the approval of domestic infliximab, Leike is facing increasingly fierce competition in the domestic market .
-
Etop Pharma's SHP2 allosteric inhibitor approved for clinical trials in China
Time of Update: 2021-08-15
The Center for Drug Evaluation (CDE) of the National Medical Products Administration of China has announced that Etoppharma’s SHP2 allosteric inhibitor ET0038 tablet has obtained two clinical trials implied licenses, and it is planned to be developed for the treatment of advanced solid tumors with abnormal MAPK signaling pathways .
-
Hengrui Medicine: HRS2398 tablets were approved for drug clinical trials
Time of Update: 2021-08-15
have recently received the approval of the State Food and Drug Administration to issue a "Drug Clinical Trial Approval Notice" for HRS2398 tablets, and clinical trials will be launched in the near future.
-
Bayer/Merxton guanylate cyclase agonist approved in the EU for the treatment of heart failure
Time of Update: 2021-08-15
Article Source: Immediate Medicine NewsOn July 21st, Merck (MSD) and Bayer (Bayer) jointly announced that the European Commission (EC) has approved the listing of its soluble guanylate cyclase (sGC) stimulant Verquvo (vericiguat) for the treatment of adults with reduced ejection fraction Patients with symptomatic chronic heart failure who have stabilized after a recent decompensated event that required intravenous (IV) therapy .
